Rob Dillard

DocwireNews

A blood-based machine learning assay may be able to differentiate patients with ovarian cancer from healthy patients with benign ovarian masses, according to a study presented at the American Association for Cancer Research Annual Meeting 2024.Federal statistics list ovarian cancer as the&nbsp;<a href="https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/" target="_blank" rel="noopener">fifth most common cause</a> of cancer deaths among women in the United States, with a 5-year survival rate of <a href="https://seer.cancer.gov/statfacts/html/ovary.html" target="_blank" rel="noopener">approximately 50%</a>. Part of what makes ovarian cancer so deadly is that it does not typically cause symptoms in the early stages of disease, explained Jamie Medina, PhD, a postdoctoral fellow at the Johns Hopkins Kimmel Cancer Center and co-author of the study.Liquid biopsy, which can be used to analyze patient blood for evidence of tumor-derived DNA, has been explored as a way to noninvasively detect a variety of cancers; however, it has not always been effective in detecting ovarian cancer, the researchers noted. DELFI (DNA Evaluation of Fragments for Early Interception) uses a newer method of liquid biopsy analysis, known as fragmentomics, which has shown promise in enhancing test accuracy. DELFI works by detecting circulation changes in the size and distribution of cell-free DNA (cfDNA) fragments across the genome.&ldquo;The lack of efficient screening tools, combined with the asymptomatic development of ovarian cancer, contributes to late diagnoses when effective treatment options are limited,&rdquo; said Dr. Medina. &ldquo;A cost-effective, accessible detection approach could change clinical paradigms of ovarian cancer screening and potentially save lives.&rdquo;Dr. Medina and colleagues assessed fragmentomes from individuals with and without ovarian cancer using DELFI by training a machine learning algorithm to integrate the fragmentome data with plasma levels of 2 known biomarkers of ovarian cancer, proteins CA125 and HE4. They analyzed 134 women with ovarian cancer, 204 women without cancer, and 203 women with benign adnexal masses.According to the results, the screening model showed a specificity of 99%. It identified 69%, 76%, 85%, and 100% of ovarian cancer cases staged I-IV, respectively. The investigators will test this model in a larger cohort, but they noted the current data are encouraging.&ldquo;This study contributes to a large body of work from our group demonstrating the power of genome-wide cfDNA fragmentation and machine learning to detect cancers with high performance,&rdquo; said Victor Velculescu, MD, PhD, FAACR, a professor of oncology, co-director of the Cancer Genetics and Epigenetics Program at the Johns Hopkins Kimmel Cancer Center, and senior author of the study. &ldquo;Our findings indicate that this combined approach resulted in improved performance for screening compared [with] existing biomarkers.&rdquo;&nbsp;

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Blood-Based Screening Model Effectively Detects Ovarian Cancer

Gynecologic Cancer

A blood-based machine learning assay may be able to differentiate patients with ovarian cancer from healthy patients with benign ovarian masses.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe